CBD and Chronic Pain: What the Research Says (UK Guide)

Around 28 million adults in the UK live with chronic pain, and CBD is heavily marketed to them. This guide explains what chronic pain is, what the research on CBD has actually found, what NICE decided, and how to look at CBD products without being misled.

This article is general information, not medical advice. Cannabinoid products sold by THC Vape Stores are not medicines and are not intended to diagnose, treat, cure or prevent any condition. If you have a health condition, take medication, or are pregnant or breastfeeding, speak to a healthcare professional before using any cannabinoid product. Adults 18+ only.

What chronic pain is

The NHS describes chronic pain as pain that lasts longer than 12 weeks despite medication or treatment. It can follow injury or surgery, accompany conditions such as osteoarthritis, rheumatoid arthritis, fibromyalgia, endometriosis, migraine or neuropathy, or exist without an identified cause. Management usually combines movement and physiotherapy, psychological approaches, pacing and – where appropriate – medication overseen by a GP or pain clinic.

What NICE decided

In November 2019 NICE published guideline NG144 on cannabis-based medicinal products. For chronic pain in adults it recommends not offering THC, THC-with-CBD (Sativex), nabilone or dronabinol, and using CBD alone only within a clinical trial. The committee found the trial benefits small compared with the costs and uncertainties, and no evidence for CBD alone. It did recommend further research into CBD for fibromyalgia and treatment-resistant neuropathic pain. That remains the UK position.

What the research shows so far

• Most pain trials have tested THC-containing medicines, not CBD by itself. Reviews of those trials (including the 2018 Cochrane review of cannabis-based medicines for chronic neuropathic pain) found small average benefits and more side effects than placebo.
• Evidence for CBD alone is mostly preclinical: animal models of arthritis and inflammation, and topical or oral CBD in rodents. Human trials are few, small and short.
• Survey data show many people report that CBD helps them – a real finding about use and perception, but not proof of effect, because such studies have no control group and strong expectation effects.

Safety, dosing and interactions

The Food Standards Agency advises healthy adults not to take more than 10 mg of CBD a day from food supplements, and says CBD is not recommended for under-18s, people taking medication, or anyone pregnant or breastfeeding. The World Health Organization’s 2018 review found CBD generally well tolerated but flagged interactions with medicines processed by liver enzymes – relevant to people on anticoagulants, anti-epileptics, some antidepressants and many others. Common painkillers such as NSAIDs and opioids carry their own well-documented risks, which is exactly why decisions about replacing or combining them belong with a prescriber, not a shop.

How to read a CBD product honestly

• Strength is stated per bottle; divide by the volume to get milligrams per millilitre – our CBD oil strength guide does the maths.
• Ask for the batch Certificate of Analysis and check that the CBD and THC figures match the label – see how to read a COA.
• Topicals (roll-ons, gels, creams and balms) deliver CBD to the skin locally; evidence for any effect on pain is preclinical.
• Words such as “pain relief”, “medical”, “clinically proven” or “prescription strength” on CBD supplements are not permitted under UK advertising rules and are a red flag about the seller.

If you live with chronic pain

Ask your GP about a referral to a pain management service. The NICE chronic pain guideline (NG193, 2021) recommends supervised exercise programmes, psychological therapies such as CBT and ACT, and acupuncture for chronic primary pain, and advises against starting several common medicines for it. Peer-support groups and pacing techniques help many people. CBD may be something you choose to try within the FSA limits, with your prescriber’s knowledge – it should not replace that care.

Sources: NICE NG144 (2019) and NG193 (2021); Mücke et al., Cochrane Database of Systematic Reviews (2018) on cannabis-based medicines for chronic neuropathic pain; WHO Expert Committee on Drug Dependence, Cannabidiol Critical Review (2018); Food Standards Agency consumer advice on CBD; NHS guidance on chronic pain.